Antibodies News and Research

RSS

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

14 Jul 2021

Israeli study of breakthrough infections following full BNT-Pfizer vaccination, 40% immunocompromised

Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.

13 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Curia today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization.

From Curia 13 Jul 2021

Colonization by SARS-CoV-2 not synonymous with infection, screening study highlights

A new study released as a preprint on the medRxiv* server throws cold water on this notion, however, by demonstrating that in a set of asymptomatic cases, less than a tenth actually had evidence of SARS-CoV-2 infection. This finding has serious implications for the practices mentioned above, since they may be neither justifiable nor cost-effective as means to break the chain of viral transmission.

13 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Selective immunotoxins may help treat liver fibrosis

Chronic alcohol abuse and hepatitis can injure the liver and lead to fibrosis, the buildup of collagen and scar tissue. As a potential approach to treating liver fibrosis, University of California San Diego School of Medicine researchers and their collaborators are looking for ways to stop liver cells from producing collagen.

12 Jul 2021

Study could guide future treatment of multisystem inflammatory syndrome in children

Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.

12 Jul 2021

Millions of COVID-19 cases went undetected in the first six months of the pandemic, finds study

A new report published in the journal Science Translational Medicine estimates that potentially 16.8 million Americans were infected but not officially diagnosed with SARS-CoV-2 by July 2020. In addition, the results suggest there were nearly five undetected coronavirus cases for every diagnosed coronavirus infection in the first six months of the pandemic.

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.

12 Jul 2021

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Multivalent protein-based minibinders hold great promise as potential prophylactic and treatment agents, as they can retain their activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. This was revealed in a recent tour-de-force research study currently available on the bioRxiv* preprint server while the article undergoes the peer review process.

11 Jul 2021

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Researchers in Israel have conducted a study showing that the use of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appears to be safe and effective among patients with cancer.

11 Jul 2021

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Researchers in the United States have shown that targeting the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike protein could achieve broad neutralization of variants of concern.

11 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world.

9 Jul 2021

Researchers model probability of extinction of SARS-CoV-2 variant in an outbreak

However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.

9 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Why is the SARS-CoV-2 Delta variant so concerning?

As cases surge in the United States, health experts have raised the alarm that vaccinated individuals may be spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant. Over half of new infections in the U.S. are now caused by this highly transmissible variant.

9 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Antibodies News and Research

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Israeli study of breakthrough infections following full BNT-Pfizer vaccination, 40% immunocompromised

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Colonization by SARS-CoV-2 not synonymous with infection, screening study highlights

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

Selective immunotoxins may help treat liver fibrosis

Study could guide future treatment of multisystem inflammatory syndrome in children

Millions of COVID-19 cases went undetected in the first six months of the pandemic, finds study

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

Researchers model probability of extinction of SARS-CoV-2 variant in an outbreak

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Why is the SARS-CoV-2 Delta variant so concerning?

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News